Natural Immunity - re-infection rare, severe illness even rarer, deaths ZERO

1. “SARS-CoV-2-specific IgG antibodies, and also NAb can persist among over 95% COVID-19 convalescents from 6 months to 12 months after disease onset. At least 19/71 (26%) of COVID-19 convalescents (double positive in ELISA and MCLIA) had detectable circulating IgM antibody against SARS-CoV-2 at 12m post-disease onset. Notably, the percentages of convalescents with positive SARS-CoV-2-specific T-cell responses (at least one of the SARS-CoV-2 antigen S1, S2, M and N protein) were 71/76 (93%) and 67/73 (92%) at 6m and 12m, respectively. Furthermore, both antibody and T-cell memory levels of the convalescents were positively associated with their disease severity.”
[link to academic.oup.com (secure)]

2. “Our analysis demonstrates that SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant for a symptomatic disease as well…. This analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalization due to the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.”
[link to www.medrxiv.org (secure)]

3. “The SARS-CoV-2 Delta variant might cause high viral loads, is highly transmissible, and contains mutations that confer partial immune escape. Outbreak investigations suggest that vaccinated persons can spread Delta. We compared RT-PCR cycle threshold (Ct) data from 699 swab specimens collected in Wisconsin 29 June through 31 July 2021 and tested with a qualitative assay by a single contract laboratory. Specimens came from residents of 36 counties, most in southern and southeastern Wisconsin, and 81% of cases were not associated with an outbreak. During this time, estimated prevalence of Delta variants in Wisconsin increased from 69% to over 95%. Vaccination status was determined via self-reporting and state immunization records.”
[link to www.medrxiv.org (secure)]

4. “Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before.”
[link to www.medrxiv.org (secure)]

5. “This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.”
[link to www.medrxiv.org (secure)]

6. “While both infection and vaccination induced robust innate and adaptive immune responses, our analysis revealed significant qualitative differences between the two types of immune challenges. In COVID-19 patients, immune responses were characterized by a highly augmented interferon response which was largely absent in vaccine recipients.”
[link to papers.ssrn.com (secure)]

7. “This study sought to determine whether infection with SARS-CoV-2 induces antigen-specific long-lived BMPCs in humans. We detected SARS-CoV-2 S-specific BMPCs in bone marrow aspirates from 15 out of 19 convalescent individuals, and in none from the 11 control participants…. Overall, our results are consistent with SARS-CoV-2 infection eliciting a canonical T-cell-dependent B cell response, in which an early transient burst of extrafollicular plasmablasts generates a wave of serum antibodies that decline relatively quickly. This is followed by more stably maintained levels of serum antibodies that are supported by long-lived BMPCs.”
[link to www.nature.com (secure)]

8. “Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. We evaluated 254 COVID-19 patients longitudinally from early infection and for eight months thereafter and found a predominant broad-based immune memory response. SARS-CoV-2 spike binding and neutralizing antibodies exhibited a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. In addition, there was a sustained IgG+ memory B cell response, which bodes well for a rapid antibody response upon virus re-exposure.”
[link to www.medrxiv.org (secure)]

9. “Previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with decreased risk for infection or re-infection with SARS-CoV-2 in a routinely screened workforce. The was no difference in the infection incidence between vaccinated individuals and individuals with previous infection. Further research is needed to determine whether our results are consistent with the emergence of new SARS-CoV-2 variants.”
[link to www.medrxiv.org (secure)]

10. “Interestingly, clonally expanded CD8 T cells were observed in every vaccinee, as observed following natural infection. TCR gene usage, however, was variable, reflecting the diversity of repertoires and MHC polymorphism in the human population. Natural infection induced expansion of larger CD8 T cell clones occupied distinct clusters, likely due to the recognition of a broader set of viral epitopes presented by the virus not seen in the mRNA vaccine. Our study highlights a coordinated adaptive immune response where early CD4 T cell responses facilitate the development of the B cell response and substantial expansion of effector CD8 T cells, together capable of contributing to future recall responses.”
[link to www.biorxiv.org (secure)]

11. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status, Jason Neidleman, Xiaoyu Luo, Matthew McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan. BioRxiv, July 29, 2021. “In infection-naïve individuals, the second dose boosted the quantity and altered the phenotypic properties of SARS-CoV-2-specific T cells, while in convalescents the second dose changed neither. Spike-specific T cells from convalescent vaccinees differed strikingly from those of infection-naïve vaccinees, with phenotypic features suggesting superior long-term persistence and ability to home to the respiratory tract including the nasopharynx. These results provide reassurance that vaccine-elicited T cells respond robustly to emerging viral variants, confirm that convalescents may not need a second vaccine dose, and suggest that vaccinated convalescents may have more persistent nasopharynx-homing SARS-CoV-2-specific T cells compared to their infection-naïve counterparts.”
[link to www.biorxiv.org (secure)]

12. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn M. Hastie, et al., Science, January 6, 2021. “Understanding immune memory to SARS-CoV-2 is critical for improving diagnostics and vaccines, and for assessing the likely future course of the COVID-19 pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months post-infection. IgG to the Spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month post symptom onset. SARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a half-life of 3-5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.”
[link to www.ncbi.nlm.nih.gov (secure)]

13. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection, by Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Merit Melin. MedRxiv, July 16, 2021. “We assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection six and twelve months after diagnosis in 367 individuals of whom 13% had severe disease requiring hospitalization. We determined the SARS-CoV-2 spike (S-IgG) and nucleoprotein IgG concentrations and the proportion of subjects with neutralizing antibodies (NAb).”
[link to www.medrxiv.org (secure)]

14. Quantifying the risk of SARS‐CoV‐2 reinfection over time, by Eamon O Murchu, Paula Byrne, Paul G. Carty, et al. Rev Med Virol. 2021. “Reinfection was an uncommon event (absolute rate 0%–1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study esti- mated the population‐level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1% [95% CI: 0.08–0.11%]) with no evidence of waning immunity for up to 7 months following primary infection. These data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection. However, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain.”
[link to www.ncbi.nlm.nih.gov (secure)]

15. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, by Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek. The Lancet, July 27, 2021. “Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months.”
[link to www.thelancet.com (secure)]

16. Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants, by Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati. MedRxiv, July 19, 2021. “These findings reinforce the strong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent, but also safeguards against progression to severe COVID-19 disease.”
[link to www.medrxiv.org (secure)]

17. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel, by Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al.. MedRxiv, April 24, 2021. “Similarly, the overall estimated level of protection from prior SARS-CoV-2 infection for documented infection is 94·8% (CI:[94·4, 95·1]); hospitalization 94·1% (CI:[91·9, 95·7]); and severe illness 96·4% (CI:[92·5, 98·3]). Our results question the need to vaccinate previously-infected individuals.”
[link to www.medrxiv.org (secure)]

18. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection, by Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al. Front Immunol. March 11, 2021. “Using HLA class II predicted peptide megapools, we identified SARS-CoV-2 cross-reactive CD4+ T cells in around 66% of the unexposed individuals. Moreover, we found detectable immune memory in mild COVID-19 patients several months after recovery in the crucial arms of protective adaptive immunity; CD4+ T cells and B cells, with a minimal contribution from CD8+ T cells. Interestingly, the persistent immune memory in COVID-19 patients is predominantly targeted towards the Spike glycoprotein of the SARS-CoV-2. This study provides the evidence of both high magnitude pre-existing and persistent immune memory in Indian population.”
[link to pubmed.ncbi.nlm.nih.gov (secure)]

28. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands, by Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríheim Kristiansen, et al, Open Forum Infectious Diseases, Volume 8, Issue 8, August 2021. “Although the protective role of antibodies is currently unknown, our results show that SARS-CoV-2 antibodies persisted at least 12 months after symptom onset and maybe even longer, indicating that COVID-19-convalescent individuals may be protected from reinfection. Our results represent SARS-CoV-2 antibody immunity in nationwide cohorts in a setting with few undetected cases, and we believe that our results add to the understanding of natural immunity and the expected durability of SARS-CoV-2 vaccine immune responses. Moreover, they can help with public health policy and ongoing strategies for vaccine delivery.
[link to academic.oup.com (secure)]

29. Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar, by Roberto Bertollini, MD, MPH1; Hiam Chemaitelly, MSc2; Hadi M. Yassine. JAMA Research Letter, June 9, 2021. “Of 9180 individuals with no record of vaccination but with a record of prior infection at least 90 days before the PCR test (group 3), 7694 could be matched to individuals with no record of vaccination or prior infection (group 2), among whom PCR positivity was 1.01% (95% CI, 0.80%-1.26%) and 3.81% (95% CI, 3.39%-4.26%), respectively. The relative risk for PCR positivity was 0.22 (95% CI, 0.17-0.28) for vaccinated individuals and 0.26 (95% CI, 0.21-0.34) for individuals with prior infection compared with no record of vaccination or prior infection.”
[link to academic.oup.com (secure)]

Did you even read any of those articles.

If you did, I know you didn't understand any of them.

if immunity doesn't exist from exposure, it can not exist from vaccination.

-at least 12 months and likely a lifetime.

remember the reports of people who had been exposed to mumps in the past had natural immunity to coronavirus?

As opposed to 10 weeks with a vaccine lol

how long until the immune system eventually gives up fighting it?

we know from previous studies that long term infection tends to get ignored by the immune system after a long battle with it.

so the end result will likely be that the people who constantly have spike proteins present will eventually start to ignore coronavirus infections and they will run rampant in their bodies.

Blah blah blah
"Natural immunity" is BS, just like the rest of their bogus science.
People can get the sniffles time and again.

# ShowmMeTheVirus

Not recognizing natural immunity is a crime and anti science.

Nobody who is recently infected should ever get a vaccine. The already very deadly and ineffective covid vaccines become many times more deadly when injected into a previously infected person.

All nations jabbing people without testing for previous infection are not scientifically administering the jabs and are killing people with the vaccines.

All nations not recognizing natural immunity have absolutely no business doing anything in the health care or vaccination realm. They are proven to be 100% incompetent and unscientific when they do not fully recognize the only immunity that can be acquired today without being in an unlawful human experiment that absolutely nobody knows the long term harmful results from it.

It is time to end every health organization who has proven to be incompetent in ignoring the only immunity that is safe to acquire.....natural immunity.

The concern here is that the vaccines are leaky and don't prevent transmission. This has been my concern in this. We could create the conditions for a virusto emerge that will kill all the unvaccinated and vaccinated. I will explain.

As the "Pandemic of the Unvaccinated" narrative crumbles under the Omicron onslaught, be ready for a switch to a different narrative. That is the untruthful narrative that not being 100% vaccinated is driving the ongoing pandemic, and that the unvaccinated are somehow still to blame by allowing variants to emerge. The "none of us is safe, until we are all safe" catchphrase.

This would be the biggest lie yet, and boy have we had a few in the last 2 years. This would directly contradict the Survival Of The Fittest principle of the Theory of Evolution. Basically it is the survival instinct that drives evolution, mutation is that evolution. Therefore, if a virus can freely spread there is no mutation or differentiation impulse. It is only when it encounters a roadblock that its ability to spread is challenged that it tries to change to get past the roadblock. The key here is infection and transmission.

Effective tradtional neutralising vaccines like those for mumps, measles, etc will prevent transmission very effectively by preventing infection.

Leaky vaccines, on the other hand, that don't prevent infection and transmission, but may reduce severity, encourage the virus to enter, mutate and the virus particles most likely to evade the vaccine roadblock are the ones that survive. Those most likely to continue to spread. Leaky vaccines will drive mutation. This has been demonstrated in controlled experiments. The mutations are the Survival of the Fittest winners. It's called the Imperfect Vaccine Hypothesis.

We are lucky that at the moment the evolutionary impetus has been to enable the virus to spread more effectively, rather than to be more damaging to the host. But this cannot be guaranteed to continue. Indeed where other leaky vaccines have been used, like in chickens, they have taken a more deadly turn.

In the world of antibiotics, failing to kill off the bacteria totally produces antibiotic resistant superbugs. We already know this. Many studies show that the same may apply to viruses.

I have added a few articles that deal with the dangers of leaky vaccines. This development of superviruses has already been proved with the Mareks Disease in chickens. Leaky avian flu vaccine use has been very limited or banned because of this very danger. Birds are culled to stop the spread, rather than risk vaccinating then with leaky vaccines that could produce a highly deadly variant that could also threaten humans.

However, we seem to have thrown caution to the wind with this Covid vaccine. The 0.096% fatality rate simply does not justify the risks we are taking. What we are seeing, with bigger and bigger waves after each vaccination or booster push is showing that the virus is responding to what we do. This is not natural. The fact that we are seeing most of the mutations in the spike proteins, that are targeted by the vaccines, is an indication that this is driving the mutations. The waves should be getting smaller.

We are literally gambling with the survival of the human race and could be creating the perfect evolutionary conditions for an Extinction Level Event virus to emerge that could kill both the vaccinated and unvaccinated.

[link to www.pbs.org (secure)]

[link to pubmed.ncbi.nlm.nih.gov (secure)]

[link to www.ncbi.nlm.nih.gov (secure)]

[link to www.nationalgeographic.com (secure)]

Everyone should print out that list of articles and keep them at work to show to coworkers.

Personally, I am beginning to think that the only survivors of this will be those that have recovered and have natural immunity and have not been vaccinated.

A Mareks Disease scenario could be fatal for those non vaccinated who have not been exposed to and recovered from the virus.

Antibody Dependent Enhancement will kick in and start to threaten those who have non neutralising antibodies created by Vaccination.

Last Edited by Online Rebel on 01/10/2022 09:34 AM

And provide them to any employer threatening them with termination for not being vaccinated.

‘Vaccinated, recovered or dead’: Germany gives stark winter warning to its people

I think the German Health Minister was indicating the first stage, A Mareks Disease scenario where a supervirus evolves (or is released) that is fatal to non-recovered, unvaccinated people.

The next stage is Antibody Dependent Enhancement ADE which targets all those that have the non neutralising antibodies that are vaccine induced.

[link to www.cnbc.com (secure)]

Last Edited by Online Rebel on 01/10/2022 09:41 AM

Missed all of these


19. Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2, by Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et al, MedRxiv, May 11, 2021. “ No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 and critical patients. However, a significant decrease in neutralisation ability was found for 20I/501Y.V1 in comparison with 19A isolate for critical patients and HCWs 6-months post infection. Concerning 20H/501Y.V2, all populations had a significant reduction in neutralising antibody titres in comparison with the 19A isolate. Interestingly, a significant difference in neutralisation capacity was observed for vaccinated HCWs between the two variants whereas it was not significant for the convalescent groups.”
[link to www.medrxiv.org (secure)]

20. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection, by Nina Le Bert, Hannah E. Clapham, Anthony T. Tan, Wan Ni Chia, et al, Journal of Experimental Medicine, March 1, 2021. “Thus, asymptomatic SARS-CoV-2–infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response.”
[link to www.nature.com (secure)]

21. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jae Hyung Jung, Min-Seok Rha, Moa Sa, Hee Kyoung Choi, Ji Hoon Jeon, et al, Nature Communications, June 30, 2021. “In particular, we observe sustained polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. Among SARS-CoV-2-specific CD4+ and CD8+ T cells detected by activation-induced markers, the proportion of stem cell-like memory T (TSCM) cells is increased, peaking at approximately 120 DPSO. Development of TSCM cells is confirmed by SARS-CoV-2-specific MHC-I multimer staining. Considering the self-renewal capacity and multipotency of TSCM cells, our data suggest that SARS-CoV-2-specific T cells are long-lasting after recovery from COVID-19, thus support the feasibility of effective vaccination programs as a measure for COVID-19 control.”
[link to www.biorxiv.org (secure)]

22. Antibody Evolution after SARS-CoV-2 mRNA Vaccination, by Alice Cho, Frauke Muecksch, Dennis Schaefer-Babaget lost peopleijun Wang, et al, BioRxiv, et al, BioRxiv, July 29, 2021. “We conclude that memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines would produce a quantitative increase in plasma neutralizing activity but not the qualitative advantage against variants obtained by vaccinating convalescent individuals.” Newer version reads: “These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with breadth equivalent to those obtained by vaccinating convalescent individuals.”

23. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals, by Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. Et al., BioRxiv, March 27, 2021. “While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naïve individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has been questioned. Here we characterized SARS-CoV-2 spike-specific humoral and cellular immunity in naïve and previously infected individuals during full BNT162b2 vaccination. Our results demonstrate that the second dose increases both the humoral and cellular immunity in naïve individuals. On the contrary, the second BNT162b2 vaccine dose results in a reduction of cellular immunity in COVID-19 recovered individuals, which suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.”
[link to www.biorxiv.org (secure)]

24. COVID-19 natural immunity: Scientific Brief. World Health Organization. May 10, 2021. “Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months). Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein.”
[link to apps.who.int (secure)]

25. SARS-CoV-2 re-infection risk in Austria, by Stefan Pilz, Ali Chakeri, John Pa Ioannidis, et al. Eur J Clin Invest. April 2021. “We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13). We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.”
[link to pubmed.ncbi.nlm.nih.gov (secure)]

26. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population, by Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al, MedRxiv, July 5, 2021. “We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.”
[link to www.medrxiv.org (secure)]

27. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN), by Victoria Jane Hall, FFPH, Sarah Foulkes, MSc, Andre Charlett, PhD, Ana Atti, MSc, et al. The Lancet, April 29, 2021. “A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection. This time period is the minimum probable effect because seroconversions were not included. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals.”
[link to www.thelancet.com (secure)]

Last Edited by Online Rebel on 01/10/2022 09:51 AM

Well said!

Agenda

I made a T Shirt that simply said:

NATURAL IMMUNITY

Guess what - banned from Etsy for disinformation!

how about one that simply says on the back IMMUNE..

Wow, that is just crazy

I mean how dumb can you be not to realise that a virus contains over 20 proteins. The vaccine is exposing your immune system to just 1.

You really don't need to be a genius to understand that any immunity from a vaccine is totally inferior.

Last Edited by Online Rebel on 01/10/2022 10:56 AM

Nice one lol

Herd Immunity just like President Trump urged.

I am old enough to remember chicken pox and measles parties where our Mothers would visit the homes of sick children to expose us and get it over with.

We didn't get all of the vaccines the kids get today, we didn't need them.

Just saying...

The covid vaccine is a population control measure to one degree or another.

Where are the studies regarding the impact that these "vaccines" have on those who have acquired natural immunity. Is there a negative impact, and is that one of the reasons that they want to force the shots on everybody?

CDC Director Rochelle Walensky: “Our vaccines are working exceptionally well … but what they can’t do anymore is prevent transmission.”

not really understanding your thoughts. your first 2 paragraphs contradict, unless i am missing something.

One thing is clear, you sure don't understand them.

I know 3 people who have now had covid 3 times
1 was vaxed after the first bout and has not gotten a booster
1 refuses to be vaxed
1 was vaxed after the second bout and had the booster

Like the common cold and other coronaviruses and rhinoviruses, the human immune system does not seem well versed in resisting the virus whether naturally or assisted.